Andrea S. James
Known title: Chief Financial OfficerCIK: 0002027010
Andrea S. James's purchase track record
How the stock did after each of Andrea S. James's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since October 2, 2024
Stock higher 6 months later
67%
3 months: 67%
Median 6-month return
+27.9%
3 months: +42.8%
Beat the S&P 500
67%
median +21.8% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/7/2025 | IMDX | $200K | +42.8% | +27.9% | +6.0% |
| 12/5/2024 | IMDX | $46K | +58.3% | +29.1% | -2.2% |
| 10/2/2024 | IMDX | $100K | -23.6% | -3.3% | -0.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| IMDX | ▲ Buy | Option Exercise | 28,302 | — | 3/26/2026 | View on chart |
| IMDX | ▼ Sell | Tax Withholding | 11,298 | $46K | 3/26/2026 | View on chart |
| IMDX | ▲ Buy | Option Exercise | 50,000 | $0 | 10/31/2025 | View on chart |
| IMDX | ▲ Buy | Open Market | 97,561 | $200K | 2/7/2025 | View on chart |
| IMDX | ▲ Buy | Open Market | 20,000 | $46K | 12/5/2024 | View on chart |
| IMDX | ▲ Buy | Open Market | 33,670 | $100K | 10/2/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
iMDx Amends Chronix Merger Deal Terms
Insight Molecular Diagnostics has amended its merger agreement with Chronix. The change replaces an ongoing 10% royalty on CNI Monitor sales with a one-time 10% payment upon the sale of the CNI Monitor. This structural shift alters the future revenue stream associated with the partnership, moving from recurring income to a single transaction-based payment.
iMDx Amends Chronix Merger Deal Terms. Insight Molecular Diagnostics has amended its merger agreement with Chronix. The change replaces an ongoing 10% royalty on CNI Monitor sales with a one-time 10% payment upon the sale of the CNI Monitor. This structural shift alters the future revenue stream associated with the partnership, moving from recurring income to a single transaction-based payment.